• Home >
  • Patent Trends across Oncolytic Virotherapy-Genetic Alert

Patent Trends across Oncolytic Virotherapy-Genetic Alert

01-Apr-2016  /  Research Code: D758-00-0D-00-00  /  SKU: HC02860-GL-TA_20521  /  
Region: Global

USD 1,500.00

* Required Fields

USD 1,500.00

PAY BY INVOICE

Be the first to review this product

This edition of the Genetic Alert depicts the current patent landscape and the new life sciences trends across oncolytic virotherapy. Analyst insights on oncolytics viral therapies are also included.The Genetic Alert presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of

Table of Contents

Patent Trends across Oncolytic Virotherapy-Genetic AlertPatent Trend-Based ProfilesOncolytic Viruses and Virotherapy a Rapidly Evolving Space in the Future of Cancer Therapeutics Genelux Corporation has the Highest Number of Granted PatentsKey Granted Patents from the Top Applicants (2012 to 2016) Key Granted Patents from the Top Applicants (2012-2016) Oncolytic Viral Therapies Entering Late Stage Clinical TrialsReovirus Therapy shows Statistical Significance in Reducing Tumor Burden among Ovarian Cancer PatientsCompanion Imaging Modality Works Synergistically with Oncolytic Viral TherapyStrategic PerspectivesStrategic TrendsAppendixIndustry Interactions




Keyword1

Keyword2

Keyword3

Related Research

Innovations in Implantable Devices, Anti-microbial Textiles, 3D Bioprinting, Cardiovascular Devices, and Bone Grafts

Release Date : 15-Jun-18

Region : Global

Innovations in Chemotherapy Personalization, Cell Transplants, Multi-drug Resistance Studies, and Adult Stem Cell Regeneration

Release Date : 08-Jun-18

Region : Global

Technology Companies to Action--Point-of-care Diagnosis of Brain Injury

Release Date : 06-Jun-18

Region : Global

Recent Advances in Targeted Therapies

Release Date : 01-Jun-18

Region : Global

Technology Companies to Action--Novel Selective Inhibitors Addressing Neurologic and Endocrine System Diseases

Release Date : 31-May-18

Region : Global

Related Subscription

• One-2-One Analyst briefing call •
• Access to published and new research deliverables •
• Mid year service review •
• Virtual Analyst briefing •
• GIL conference seats •

Why Frost & Sullivan

Vision & Strategy

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Brand & Demand

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Technology & IP

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

Global Prespective

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.